The pharmacokinetics trial, which included 60 participants with seasonal allergies, also demonstrated rapid drug absorption with the intranasal spray.
Adenoidectomy and tonsillectomy in children by age 9 were associated with higher long-term risks for respiratory, infectious, and allergic diseases.
Vitamin D supplementation appears to reduce the recurrent wheezing by 12 months of age in black infants born prematurely.
Researchers developed a predictive algorithm to identify individuals with a higher risk for severe reactions to the standardized peanut oral food challenge.
Fluticasone Propionate Nasal Spray is a corticosteroid indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adults and pediatric patients aged 4 years and older.
Montelukast improved symptoms in a significant proportion of individuals with angioedema-predominant chronic spontaneous urticaria.
Many parents feel additional food labeling, allergy education, and stocking of epinephrine are needed.
The pattern of laryngeal motor dysfunction and the prevalence and severity of laryngeal hypersensitivity in individuals with chronic cough were similar to that observed in individuals with vocal cord dysfunction and muscle tension dysphonia.
A strong dose-response relation was seen with atopic eczema severity.
Researchers have developed a novel algorithm to identify hypersensitivity pneumonitis.
Nasal beclomethasone dipropionate was more effective in improving nasal patency and cytology as well as quality of life compared with cetirizine in children with perennial allergic rhinitis.
Physiological lipids in the products restored skin barrier function and hydration.
Potential risk factors for eosinophilic esophagitis include antibiotic use in infancy and behaviors such as smoking and alcohol intake.
Intermittent supply constraints due to manufacturing delays from Mylan's manufacturing partner, Meridian Medical Technologies, have resulted in varying supply levels.
Patient-oriented eczema measures cores did not meet the minimal clinically important difference after adjustment for confounders.
The supplemental New Drug Application (sNDA) for the 0.1mg strength was granted Priority Review by the Food and Drug Administration (FDA).
Intake of birch-pollen related foods may lead to aggravation of symptoms in patients with atopic dermatitis.
Higher parental income was the only significant positive predictor of willingness to enroll child in a clinical trial.
Only 16.5% of pharmacy customers with hay fever select optimal medications.
Findings for subsequent allergic disease following infant exposure in the first six months of life.